Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab
Gil Awada(Mathys (Netherlands)), Bart Neyns(Universitair Ziekenhuis Brussel), Yanina Jansen(Universitair Ziekenhuis Brussel), Marleen Keyaerts(Vrije Universiteit Brussel), Odrade Gondry(Onze Lieve Vrouwziekenhuis Hospital), Teofila Seremet(University of Lausanne), Elizabeth A Daeninck(Universitair Ziekenhuis Brussel), Hendrik Everaert(Universitair Ziekenhuis Brussel), İsa Aykut Özdemir(Bakırköy Dr.Sadi Konuk Eğitim ve Araştırma Hastanesi), Jürgen Schwarze(University of Freiburg)
Cited by 4
Related Papers
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
|Annals of Oncology|2022|253
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
|Annals of Oncology|2020|232
Hypoxia shapes the immune landscape in lung injury and promotes the persistence of inflammation
|Nature Immunology|2022|79